Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | FCER2 | P06734 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 2/20 | 0.38 |
| ▸ | CCR3 | P51677 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2837048 | 0.90 | PKM (0.39) | MEN1KMT2ASMN1; SMN2LMNAPKM | |
| SCHEMBL2841930 | 0.76 | HPGD (0.46) | MEN1KMT2ASMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL2841931 | 0.76 | HPGD (0.46) | MEN1KMT2ASMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL8938677 | 0.70 | MEN1 (0.43) | MEN1KMT2APKMHPGDF2 | |
| SCHEMBL4412431 | 0.69 | L3MBTL1 (0.46) | MEN1KMT2AHPGDCYP1A2CYP2C9 | |
| SCHEMBL2422679 | 0.68 | HPGD (0.44) | MEN1KMT2ASMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL2422683 | 0.66 | HPGD (0.42) | MEN1KMT2ASMN1; SMN2LMNAPKM | |
| SCHEMBL2837051 | 0.66 | HPGD (0.49) | MMP1FCER2PKMHPGDCYP1A2 | |
| SCHEMBL9535465 | 0.65 | HPGD (0.57) | MEN1KMT2AHPGDCYP1A2CYP2C9 | |
| SCHEMBL1598713 | 0.64 | HPGD (0.42) | MEN1KMT2ASMN1; SMN2LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7667044-B2 | treating nervous system diorders such as Alzheimer's disease, Down Syndrome, Parkinson disease and Huntington chorea by administering inhibitors of prolyl endopeptidases | PROBIODRUG AG (DE) | 2010-02-23 | — | — | US | disclosed |
| EP-1824846-A2 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Probiodrug AG (DE) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006058720-A2 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PROBIODRUG AG (DE) | 2006-06-08 | — | — | WO | disclosed |
| US-20060100253-A1 | Novel compounds for the treatment of neurological disorders | PROBIODRUG AG | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100253-A1 | Novel compounds for the treatment of neurological disorders | PREP, BACE1, BCHE | MEN1 1661/4885KMT2A 863/4885SMN1; SMN2 1499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.